Auspex Pharmaceuticals Overview
- Founded
- 2001

- Status
- Acquired/Merged
- Employees
- 37

- Latest Deal Type
- M&A
- Latest Deal Amount
- $3.5B

Auspex Pharmaceuticals General Information
Description
Developer of deuterated analogs of clinically-validated drugs. The company develops a pipeline of therapeutics that improves on existing drugs across various therapeutic areas. It focuses on the development of drugs for the treatment of involuntary movement disorders, respiratory disease and inflammation.
Contact Information
- 3366 North Torrey Pines Court
- Suite 225
- San Diego, CA 92037
- United States
Auspex Pharmaceuticals Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
16. Merger/Acquisition | 05-May-2015 | $3.5B | 00000 | 00.00 | Completed | Clinical Trials - Phase 3 |
15. 2PO | 23-Jan-2015 | 00000 | 00000 | Completed | Clinical Trials - Phase 3 | |
14. 2PO | 11-Jul-2014 | 000.00 | 00000 | 00000 | Completed | Clinical Trials - Phase 3 |
13. IPO | 05-Feb-2014 | 0000 | 00000 | 00000 | Completed | Clinical Trials - Phase 3 |
12. Debt - General | 08-Jan-2014 | 0000 | 00000 | Completed | Clinical Trials - Phase 3 | |
11. Later Stage VC (Series E) | 20-Dec-2013 | 000.00 | 00000 | 00000 | Completed | Clinical Trials - Phase 3 |
10. Later Stage VC (Series D) | 06-Sep-2013 | 0000 | 0000 | 000.00 | Completed | Clinical Trials - Phase 3 |
9. Debt - General | 11-Mar-2013 | 0000 | Completed | Clinical Trials - Phase 3 | ||
8. Later Stage VC | 09-Nov-2012 | $19M | $70M | Completed | Clinical Trials - Phase 3 | |
7. Later Stage VC | 28-Dec-2011 | $3M | $51M | Completed | Generating Revenue |
Auspex Pharmaceuticals Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series E | 00,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
Series D | 00,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.00 |
Series C | 00,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
Series B | 0,000,000 | 00.000000 | 00 | 00.0 | 00.0 | 00 | 00.0 | 0.000 |
Series A5 | 00,000 | 00.000000 | 00 | 00.0 | 00.0 | 00 | 00.0 | 0.000 |
Series A4 | 000,000 | 00.000000 | 00 | 00.0 | 00.0 | 00 | 00.0 | 0.000 |
Series A3 | 000,000 | 00.000000 | 00 | 00.0 | 00.0 | 00 | 00.0 | 0.000 |
Series A2 | 610,294 | $0.000100 | 8% | $1.7 | $1.7 | 1x | $1.7 | 0.87% |
Series A1 | 613,500 | $0.000100 | 8% | $1 | $1 | 1x | $1 | 0.88% |
Auspex Pharmaceuticals Comparisons
Industry
000 0000
0000 000
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialAuspex Pharmaceuticals Competitors (77)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Hua Medicine | Formerly VC-backed | Pudong, China | 000 | 00000 | 00000000 | 00000 |
0000 000000 | Formerly VC-backed | San Diego, CA | 00 | 00000 | 00000000 | 00000 |
000000 00000000000 | Formerly VC-backed | Boston, MA | 0000 | 00.000 | 000000&0 | |
0000000 | Venture Capital-Backed | Framingham, MA | 00 | 000.00 | 00000000000 | 000.00 |
00000 | Formerly VC-backed | Cambridge, MA | 000 | 00000 | 000000&0 |
Auspex Pharmaceuticals Patents
Auspex Pharmaceuticals Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
EP-3893876-A1 | Deutetrabenazine for the treatment of dyskinesia in cerebral palsy | Pending | 13-Dec-2018 | 00000000000 | |
AU-2019395250-A1 | Deutetrabenazine for the treatment of dyskinesia in cerebral palsy | Pending | 13-Dec-2018 | 00000000000 | |
US-20200188371-A1 | Methods for the treatment of dyskinesia in cerebral palsy | Pending | 13-Dec-2018 | 00000000000 | |
CA-3123393-A1 | Deutetrabenazine for the treatment of dyskinesia in cerebral palsy | Pending | 13-Dec-2018 | 00000000000 | |
US-20200016148-A1 | Analogs of deutetrabenazine, their preparation and use | Granted | 15-Mar-2017 | A61K31/4745 |
Auspex Pharmaceuticals Signals
Growth Rate

Growth

Size Multiple


Key Data Points
Twitter Followers
5.5k

Similarweb Unique Visitors
15.0K

Majestic Referring Domains
314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialAuspex Pharmaceuticals Former Investors (9)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
BioMed Ventures | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | |
Costa Verde Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
Deerfield Management | Venture Capital | Minority | 000 0000 | 000000 0 | |
Foresite Capital Management | Growth/Expansion | Minority | 000 0000 | 000000 0 | |
Panorama Capital | Venture Capital | Minority | 000 0000 | 000000 0 |